Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Rheumatoid Arthritis
Interventions: CP-690,550, Methotrexate, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 59
States / cities: Huntsville, Alabama • Gilbert, Arizona • Peoria, Arizona + 48 more

Conditions: Parkinson Disease, Parkinsons Disease With Dementia
Interventions: Placebo Oral Capsule, Nilotinib 150mg oral capsule [Tasigna], Nilotinib 300mg oral capsule [Tasigna]; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 40 Years to 90 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Agitation, Alzheimer's Disease
Interventions: AVP-923-20, Placebo, AVP-923-30; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 44
States / cities: Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more

Conditions: Hepatitis C, HCV
Interventions: TD-6450, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Acne, Premenstrual Syndrome
Interventions: Skincare Routine, MINDBODYSKIN Supplement; Other · Dietary Supplement
Lead sponsor: Clearstem Skincare; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Major Depressive Disorder
Interventions: Icalcaprant, Placebo for Icalcaprant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 33
States / cities: Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more

Conditions: Delayed Alcohol Induced Headache
Interventions: VVD-101, Placebo; Drug
Lead sponsor: Cady, Roger, M.D.; Individual
Eligibility: 21 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Mountain View, California • Springfield, Missouri

Conditions: Long COVID
Interventions: Nirmatrelvir, Ritonavir, Placebo; Drug
Lead sponsor: Harlan M Krumholz; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Ulcerative Colitis
Interventions: BBT-401-1S or Placebo; Drug
Lead sponsor: Bridge Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: Little Rock, Arkansas • Fountain Valley, California • Lancaster, California + 6 more

Conditions: Alzheimer's Disease
Interventions: NGP 555; Drug
Lead sponsor: NeuroGenetic Pharmaceuticals Inc; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Cypress, California

Conditions: Age-Related Lung Function Decline
Interventions: Fisetin, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus
Interventions: Metformin, Placebo; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 10 Years to 20 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Major Depressive Disorder
Interventions: SP-624, Placebo; Drug
Lead sponsor: Sirtsei Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 39
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 36 more

Conditions: Non Small Cell Lung Cancer
Interventions: AZD6244, docetaxel, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 1 more

Conditions: Major Depressive Disorder
Interventions: SPD489 (Lisdexamfetamine dimesylate), Matching placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 33
States / cities: Imperial, California • Los Alamitos, California • Oceanside, California + 28 more

Conditions: Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
Interventions: HTD1801, Placebo; Drug
Lead sponsor: HighTide Therapeutics (Hong Kong) Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 43
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more

Conditions: Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode
Interventions: SAGE-217, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 11
States / cities: Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 8 more

Conditions: Endometriosis, Endometriosis Related Pain, Endometriosis, Pain
Interventions: Dronabinol Capsules, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Hosuton, Texas • Houston, Texas

Conditions: Premenstrual Syndrome, Women Health
Interventions: Shatavari Root Extract, Placebo Capsule; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Valsartan 160 mg + nateglinide 60 mg, Valsartan 160 mg + nateglinide placebo, Nateglinide 60 mg + valsartan placebo, Valsartan placebo + nateglinide placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 99 Years
Enrollment: 9,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Multiple Locations, New Jersey

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency, Iron-deficiency Anemia (IDA)
Interventions: Ferric Carboxymaltose, Ferrous Sulfate; Drug
Lead sponsor: Syed Hamza Mufarrih; Other
Eligibility: 18 Years to 100 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bowling Green, Kentucky

Conditions: Hot Flashes
Interventions: Brisdelle (paroxetine mesylate), Placebo capsules; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 32
States / cities: Montgomery, Alabama • Chandler, Arizona • San Diego, California + 28 more

Conditions: Vascular Diseases
Interventions: Sildenafil, Placebo; Drug · Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Bone Neoplasms, Pain, Intractable, Cancer
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 8
States / cities: Celebration, Florida • Kissimmee, Florida • Pensacola, Florida + 4 more

Search by objective public record fields.

Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

TD-6450 MAD Study in HCV Infected Subjects

An RCT Evaluating the Efficacy of a Skincare Routine and Acne Supplement on Improving Acne and Other Symptoms of PMS

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches

A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)

Ongoing Lung Decline With Age Intensified Response

Adjunctive Metformin Therapy in Double Diabetes

A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

Efficacy and Safety of Shatavari Root Extract for Premenstrual Syndrome in Women

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

Sildenafil to Reduce Vascular Remodeling During Left Ventricular Assist Device Support

A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer